Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia

Blood

Volumn 97, Issue 12, 2001, Pages 3995-3997

  Zecca, Marco ^a,b   De Stefano, Piero ^a,b   Nobili, Bruno ^a,b   Locatelli, Franco ^a,b,c  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; RITUXIMAB; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG TOLERABILITY; ERYTHROCYTE APLASIA; FEMALE; HEMOLYTIC ANEMIA; HUMAN; LYMPHOCYTE DEPLETION; PRESCHOOL CHILD; PRIORITY JOURNAL; RETICULOCYTE COUNT; TREATMENT OUTCOME;

EID: 0035877988     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.12.3995     Document Type: Article

References (18)

1. Freedman MH. Pure red cell aplasia in childhood and adolescence: pathogenesis and approaches to diagnosis. Br J Haematol. 1993;85:246-253.
2. Alter BP, Young NS. Bone marrow failure syndromes. In Nathan DG, Oski FA, eds. Hematology of infancy and childhood. Philadelphia, PA: WB Saunders; 1993:216-316.
3. Erslev AJ. Pure red cell aplasia. In Beutler E, Lichtman MA, Coller BS, Kipps TJ, eds. Williams Hematology. New York, NY: McGraw-Hill; 1995:448-456.
4. Hegde UM, Gordon-Smith EC, Worlledge SM. Reticulocytopenia and "absence" of red cell auto-antibodies in immune haemolytic anaemia. Br Med J. 1977;2:1444-1447.
5. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four dose treatment program. J Clin Oncol. 1998;16:2825-2833.
6. Reff ME, Carner K, Chambers S, et al. Depletion of B-cells in vivo by a chimeric mouse monoclonal antibody to CD20. Blood. 1994;435-445.
7. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927-1932.
8. Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol. 1998;10:548-551.
9. Maloney DJ, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90 [abstr 349]:2188-2195.
10. Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol. 1999;17:791-795.
11. CarloStella C, Ganser A, Hoelzer D. Detective "in vitro" growth of hemopoietic progenitor cells CFU-GEMM, CFU-Mk, BFU-E and CFU-GM in the acquired immunodeficiency syndrome (AIDS). J Clin Invest. 1987;80:286-290.
12. Ratanatharathorn V, Carson E, Reynolds C, et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med. 2000;133:275-279.
13. Lee E, Zamkoff KW, Gentile TC, Zimrin A. Rituxan in the treatment of autoimmune hemolytic anemia (AIHA). Blood. 2000;96(suppl 1):596a.
14. Grossi A, Santini V, Longo G, Balestri F, Rossi-Ferrini P. Treatment with anti-CD20 antibodies of patients with autoimmune thrombocytopenia with or without hemolytic anemia; worsening in the hemoglobin level. Blood. 2000;96(suppl 1):253a.
15. Berenstein S, Tjonnfjord GE, Gjertsen BT et al. Rituxan (Rituximab) therapy for chronic cold agglutinin disease. Blood. 2000;96(suppl 1):730a.
16. Rituxan: product profile and guide to clinical use. South San Francisco: Genentech Bio-Oncology and ADEC Pharmaceuticals Corporation; 1998.
17. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving Rituximab. N Engl J Med. 2001;344:68-69.
18. Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood. 2000;96:1184-1186.